Half-sandwich ruthenium complex for treating spinal cord injury and preparation method thereof

By developing the semi-sandwich ruthenium complex Ru-PA, the removal of reactive oxygen by fluorine and bioimaging technology was used to solve the problem of oxidative stress in spinal cord injury, the protection and regeneration of spinal cord neurons was achieved, and the spinal cord injury mice were significantly improved. Functions, providing new therapeutic ideas and sources of drugs.

CN118754916BActive Publication Date: 2024-11-29JINAN UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411252627.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-09
Publication Date
2024-11-29
Estimated Expiration
2044-09-09

AI Technical Summary

Technical Problem

The prior art is difficult to effectively remove reactive oxygen species produced in spinal cord injury, resulting in oxidative stress and neuronal death, and there is a lack of effective therapeutic strategies.

Method used

A semisandwich ruthenium complex, Ru-PA, was developed to remove reactive oxygen species, regulate proteins, protect spinal cord neurons, and promote their regeneration by combining fluorine and bioimaging techniques.

Benefits of technology

Ru-PA can significantly eliminate oxygen free radicals, promote neurite growth, repair hippocampal neuronal cells, and improve the electrical signal and motor function of spinal cord injury mice. It provides new ideas for treatment of spinal cord injury and drug sources, and is safe.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118754916B_ABST
    Figure CN118754916B_ABST
Patent Text Reader

Abstract

The present invention relates to a half-sandwich ruthenium complex for treating spinal cord injury and a preparation method thereof. The half-sandwich ruthenium complex Ru-PA provided by the present invention can effectively remove oxygen free radicals, promote branch formation and neurite growth, indicating that Ru-PA can repair hippocampal neuronal cells and resist damage induced by oxidative stress, while having no obvious toxicity to cells or tissues and having good safety. In vivo studies have shown that Ru-PA can significantly enhance the behavioral function of mice and reduce the oxidative stress response after spinal cord injury, thereby promoting the repair of spinal cord injury, improving the electrical signals and motor functions of mice with spinal cord injury, and providing a new research idea and drug source for drug treatment of spinal cord injury.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and particularly relates to a half-sandwich ruthenium complex for treating spinal cord injury and a preparation method thereof. Background Art

[0002] Spinal cord injury (SCI) is a common and serious neurological disease, mostly caused by traumatic injury. Once the spinal cord is damaged, control of higher nerve centers is lost, and sensory and motor functions below the injury site are completely or partially lost, leading to severe paralysis or death. Secondary injury of spinal cord injury is a multipathological process following primary injury, including a series of biochemical reactions, including oxidative stress, inflammatory response, and lipid peroxidation. This process produces a large amount of reactive oxygen species (ROS). The reactions triggered by these substances can destroy the subcellular structure of neurons and glial cells, leading to cell death. This may be the main reason for the poor prognosis of patients with spinal cord injury. Current research focuses on effectively removing ROS, reducing inflammation, and reducing neuronal death. Therefore, developing effective treatment strategies for secondary spinal cord injury may accelerate the recovery of patients.

[0003] Heterocyclic structures and heteroatoms play a key role in active drug molecules, and more than 20% of small molecule drugs contain heteroatoms such as fluorine. In addition, the metalation of heterocyclic systems such as naphthyrimidine has recognized potential in treating a series of diseases, making it one of the main functionalization sites for the development of small molecule chemical drugs in the future. In this regard, obtaining small molecule active compounds with significant antioxidant effects, which can be used to treat spinal cord injury and have good safety has become one of the hot issues that need to be solved urgently. Summary of the invention

[0004] The purpose of the present invention is to solve the technical problems existing in the prior art, thereby providing a pioneering strategy to combine fluorine with bioimaging technology to construct a half-sandwich ruthenium complex Ru-PA for treating spinal cord injury, which can relieve oxidative stress by scavenging reactive oxygen species and treat spinal cord injury through the mechanism of protein regulation; at the same time, it can protect spinal cord neurons and stimulate their regeneration, thereby improving the electrical signals and motor functions of mice with spinal cord injury, providing new ideas for the treatment of spinal cord injury and subsequent drug development.

[0005] In order to solve the above technical problems, the present invention is implemented through the following technical solutions.

[0006] The first aspect of the present invention provides a half-sandwich structure ruthenium complex, the structural formula of which is shown below:

[0007] The half-sandwich structure ruthenium complex is named Ru-PA.

[0008] Preferably, the half-sandwich structure ruthenium complex is prepared by the following method:

[0009] (1) Dissolve 6-fluoroquinoline 2-carboxaldehyde, 2,6-diisopropylaniline and formic acid in organic solvent 1 and stir at room temperature overnight;

[0010] (2) removing the solvent by spin drying, followed by washing and drying to obtain 2,6-diisopropyl-N-(6-fluoroquinolin-2-ylmethylene)aniline (N^N) in the form of a yellow powder;

[0011] (3) 2,6-diisopropyl-N-(6-fluoroquinolin-2-ylmethylene)aniline and [(η 6 -3-phenylpropanol-1-ol)RuCl2]2 is dissolved in organic solvent 2 and stirred; then NH4PF6 is added and the reaction is continued with stirring;

[0012] (4) The solvent was removed under reduced pressure, and the obtained product was dissolved in dichloromethane and filtered using a diatomaceous earth filter funnel. The filtrate was collected and added with n-hexane for slow diffusion and recrystallization to obtain ([(η 6 -3-phenylpropanol-1-ol)Ru(N^N)Cl]PF6,Ru-PA).

[0013] Preferably, the molar ratio of 6-fluoroquinoline 2-carboxaldehyde to 2,6-diisopropylaniline in step (1) is 1:0.5-3; most preferably, the molar ratio of 6-fluoroquinoline 2-carboxaldehyde to 2,6-diisopropylaniline is 1:1.

[0014] Preferably, in step (1), the organic solvent 1 is selected from one or more of methanol, ethanol, isopropanol, acetone, tetrahydrofuran and chloroform; most preferably, the organic solvent 1 is selected from methanol.

[0015] Preferably, the washing in step (2) is performed using water.

[0016] Preferably, the 2,6-diisopropyl-N-(6-fluoroquinolin-2-ylmethylene)aniline and [(η 6 -3-phenylpropanol-1-ol)RuCl2]2 has a molar ratio of 1:0.1-1; most preferably, 2,6-diisopropyl-N-(6-fluoroquinolin-2-ylmethylene)aniline and [(η 6 -3-phenylpropanol-1-ol)RuCl2]2 has a molar ratio of 1:0.5.

[0017] Preferably, the molar ratio of 2,6-diisopropyl-N-(6-fluoroquinolin-2-ylmethylene)aniline to NH4PF6 in step (3) is 1:1-3; most preferably, the molar ratio of 2,6-diisopropyl-N-(6-fluoroquinolin-2-ylmethylene)aniline to NH4PF6 is 1:2.

[0018] Preferably, in step (3), stirring is performed for 8-20 hours after adding the organic solvent 2.

[0019] Preferably, in step (3), stirring is performed for 3-12 hours after adding NH4PF6.

[0020] Preferably, the organic solvent 2 in step (3) is selected from one or more of methanol, ethanol, isopropanol, acetone, tetrahydrofuran, and chloroform; most preferably, the organic solvent 2 is selected from methanol.

[0021] The second aspect of the present invention provides a method for preparing a half-sandwich structure ruthenium complex, comprising the following steps:

[0022] (1) Dissolve 6-fluoroquinoline 2-carboxaldehyde, 2,6-diisopropylaniline and formic acid in organic solvent 1 and stir at room temperature overnight;

[0023] (2) removing the solvent by spin drying, followed by washing and drying to obtain 2,6-diisopropyl-N-(6-fluoroquinolin-2-ylmethylene)aniline (N^N) in the form of a yellow powder;

[0024] (3) 2,6-diisopropyl-N-(6-fluoroquinolin-2-ylmethylene)aniline and [(η 6 -3-phenylpropanol-1-ol)RuCl2]2 is dissolved in organic solvent 2 and stirred; then NH4PF6 is added and the reaction is continued with stirring;

[0025] (4) The solvent was removed under reduced pressure, and the obtained product was dissolved in dichloromethane and filtered using a diatomaceous earth filter funnel. The filtrate was collected and added with n-hexane for slow diffusion and recrystallization to obtain ([(η 6 -3-phenylpropanol-1-ol)Ru(N^N)Cl]PF6,Ru-PA).

[0026] Preferably, the molar ratio of 6-fluoroquinoline 2-carboxaldehyde to 2,6-diisopropylaniline in step (1) is 1:0.5-3; most preferably, the molar ratio of 6-fluoroquinoline 2-carboxaldehyde to 2,6-diisopropylaniline is 1:1.

[0027] Preferably, in step (1), the organic solvent 1 is selected from one or more of methanol, ethanol, isopropanol, acetone, tetrahydrofuran and chloroform; most preferably, the organic solvent 1 is selected from methanol.

[0028] Preferably, the washing in step (2) is performed using water.

[0029] Preferably, the 2,6-diisopropyl-N-(6-fluoroquinolin-2-ylmethylene)aniline and [(η 6 -3-phenylpropanol-1-ol)RuCl2]2 has a molar ratio of 1:0.1-1; most preferably, 2,6-diisopropyl-N-(6-fluoroquinolin-2-ylmethylene)aniline and [(η 6 -3-phenylpropanol-1-ol)RuCl2]2 has a molar ratio of 1:0.5.

[0030] Preferably, the molar ratio of 2,6-diisopropyl-N-(6-fluoroquinolin-2-ylmethylene)aniline to NH4PF6 in step (3) is 1:1-3; most preferably, the molar ratio of 2,6-diisopropyl-N-(6-fluoroquinolin-2-ylmethylene)aniline to NH4PF6 is 1:2.

[0031] Preferably, in step (3), stirring is performed for 8-20 hours after adding the organic solvent 2.

[0032] Preferably, in step (3), stirring is performed for 3-12 hours after adding NH4PF6.

[0033] Preferably, the organic solvent 2 in step (3) is selected from one or more of methanol, ethanol, isopropanol, acetone, tetrahydrofuran, and chloroform; most preferably, the organic solvent 2 is selected from methanol.

[0034] The third aspect of the present invention provides a pharmaceutical composition for preventing and / or treating diseases associated with oxidative stress, comprising a half-sandwich structure ruthenium complex, the structural formula of the half-sandwich structure ruthenium complex is as follows:

[0035] .

[0036] Preferably, the disease associated with oxidative stress is secondary spinal cord injury.

[0037] Preferably, the pharmaceutical composition optionally further comprises a pharmaceutically acceptable carrier.

[0038] Preferably, the pharmaceutically acceptable carrier is selected from one or more of a filler, a binder, a disintegrant, a lubricant, a preservative, a chelating agent, a flavoring agent, a colorant, a stabilizer, a solvent, and an antioxidant.

[0039] The fourth aspect of the present invention provides a use of a half-sandwich structure ruthenium complex in the preparation of a drug for preventing and / or treating diseases associated with oxidative stress, wherein the half-sandwich structure ruthenium complex has a structural formula as shown below:

[0040] .

[0041] Preferably, the disease associated with oxidative stress is secondary spinal cord injury.

[0042] The fifth aspect of the present invention provides an application of a half-sandwich structure ruthenium complex in the preparation of a drug for scavenging oxygen free radicals. The structural formula of the half-sandwich structure ruthenium complex is as follows:

[0043] .

[0044] Compared with the prior art, the present invention has the following technical effects:

[0045] The half-sandwich structure ruthenium complex Ru-PA provided by the present invention can effectively remove oxygen free radicals, promote branch formation and neurite growth, indicating that Ru-PA can repair hippocampal neuron cells and resist damage induced by oxidative stress, while having no obvious toxicity to cells or tissues and good safety. In vivo studies have shown that Ru-PA can significantly enhance the behavioral function of mice and reduce the oxidative stress response after spinal cord injury, thereby promoting the repair of spinal cord injury, improving the electrical signals and motor functions of spinal cord injured mice, and providing a new research idea and drug source for drug treatment of spinal cord injury. BRIEF DESCRIPTION OF THE DRAWINGS

[0046] Figure 1 Electronic absorption spectra of Ru-PA in different solvents.

[0047] Figure 2 is the fluorescence spectrum of Ru-PA at room temperature.

[0048] Figure 3 Schematic diagram of the results of determining the free radical scavenging ability of Ru-PA using the ABTS method.

[0049] Figure 4 The DPPH method was used to determine the free radical scavenging ability of Ru-PA.

[0050] Figure 5 Schematic diagram of ROS analysis results in HT22 cells.

[0051] Figure 6 Schematic diagram of flow cytometry detection of Ru-PA reducing intracellular ROS levels.

[0052] Figure 7Schematic diagram of the results of Ru-PA reducing intracellular ROS levels by scavenging superoxide anions.

[0053] Figure 8 Schematic diagram of the effect of Ru-PA on neuronal cell survival rate.

[0054] Fig. 9 This is a typical diagram of the protective effect of Ru-PA on neurons.

[0055] Fig.10 Schematic diagram of the effect of Ru-PA on the length and number of neuronal processes.

[0056] Fig.11 Schematic diagram of the effects of Ru-PA on ROS in SCI mice.

[0057] Fig.12 These are typical images of hind limb recovery in each group of SCI mice 60 days after spinal cord injury.

[0058] Fig.13 Schematic diagram of BMS evaluation results for each group of SCI mice.

[0059] Fig.14 Schematic diagram of footprint experiment results.

[0060] Fig.15 Schematic diagram of the inclined plate crawling experiment results.

[0061] Fig.16 Schematic diagram of the comparison of spinal cord status in each group of SCI mice.

[0062] Fig.17 Schematic diagram of H&E analysis results of the spinal cord of SCI mice in each group.

[0063] Fig.18 Schematic diagram of the co-staining results of GFAP and NFH.

[0064] Fig.19 Schematic diagram of the effect of Ru-PA on motor evoked potentials in SCI mice.

[0065] Fig. 20 Schematic diagram of the effect of Ru-PA on spinal cord signal recovery in SCI mice.

[0066] Fig.21 Schematic diagram of H&E staining analysis results of the main organs of SCI mice in each group. DETAILED DESCRIPTION

[0067] In order to make the purpose, technical scheme and effect of the present invention clearer and more specific, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0068] Unless otherwise specified, the reagents used in the context of the present invention are all commercially available. The experimental animals used in animal experiments were purchased from the Experimental Animal Center of Southern Medical University, and the relevant procedures and methods were approved by the Animal Experiment Ethics Committee of Jinan University and followed its guidelines. The experimental methods used in the present invention are all conventional methods and techniques in the art.

[0069] Representative results from repeated biological experiments were presented in the context figures, and the data were presented as mean ± SD and mean ± SEM as specified in the figures. All experiments were repeated at least three times. The data were analyzed using GraphPad Prism 8.0 or SPSS 22.0 software. Conventional medical statistical methods such as t-test, chi-square test, and analysis of variance were used to compare the mean differences between two or more groups. p A value < 0.05 was considered a significant difference.

[0070] Example 1 Preparation and characterization of half-sandwich structure ruthenium complex

[0071] A semi-sandwich structure ruthenium complex Ru-PA, the preparation method of which comprises the following steps:

[0072] (1) Dissolve 6-fluoroquinoline 2-carboxaldehyde (5 mmol, 0.875 g), 2,6-diisopropylaniline (5 mmol, 0.885 g), and formic acid (100 μL) in methanol (5 mL) and stir at room temperature overnight.

[0073] (2) The solvent was removed by evaporation to dryness on a rotary evaporator, and the obtained product was washed with 5 mL of water and dried at room temperature to obtain 2,6-diisopropyl-N-(6-fluoroquinolin-2-ylmethylene)aniline (N^N) in the form of a yellow powder; its NMR identification data are as follows: 1 HNMR (500MHz, CDCl3) δ8.51–8.41 (m, 2H), 8.29–8.18 (m, 2H), 7.54 (dt, J =11.6, 5.7Hz, 2H), 7.22–7.11 (m, 3H), 2.99 (dt, J =13.7, 6.9Hz, 2H), 1.28 (d, J =6.8Hz, 1H), 1.19(d, J =6.9Hz, 11H).

[0074] (3) 2,6-diisopropyl-N-(6-fluoroquinolin-2-ylmethylene)aniline (0.10 mmol) and [(η 6-3-phenylpropanol-1-ol) (bz-PA)RuCl2]2 (0.05 mmol) was dissolved in methanol (20 mL) and stirred for 12 h in a dry round-bottom flask equipped with a stirrer and a nitrogen atmosphere; then NH4PF6 (0.2 mmol) was added and the reaction was stirred for 6 h.

[0075] (4) After complete conversion, the solvent is removed under reduced pressure, and the obtained product is dissolved in dichloromethane and filtered using a diatomaceous earth filter funnel. The filtrate is collected and added with n-hexane for slow diffusion and recrystallization to obtain ([(η 6 -3-phenylpropanol-1-ol)Ru(N^N)Cl]PF6,Ru-PA); its NMR identification data are as follows: 1 HNMR (500MHz, DMSO) δ9.24 (s, 1H), 8.92 (d, J=8.3Hz, 1H), 8.79 (dd, J=9.6, 5.0Hz, 1H), 8.38 (d, J=8.3Hz, 1H), 8.21 (dd, J=8.7 , 2.9Hz, 1H), 8.10–8.03 (m, 1H), 7.63–7.51 (m, 2H), 7.51–7.44 (m, 1H), 6.49–6.36 (m, 2H), 5.74 (dd, J=11.5, 5.9Hz, 1H), 5.35 –5.24 (m, 2H), 4.62 (t, J=5.0Hz, 1H), 3.82 (dt, J=16.6, 8.2Hz, 1H), 3.49–3.40 (m, 2H), 2.77–2.70 (m, 1H), 2.43 (dd, J=13.3, 7 .6Hz, 2H), 1.83–1.71 (m, 2H), 1.40 (d, J=6.7Hz, 3H), 1.28 (dd, J=29.0, 6.7Hz, 6H), 0.88 (d, J=6.7Hz, 3H).Anal.Calcd.For[(η 6 -bz-PA)Ru(L1)Cl]PF6(752.11): C, 49.51; H, 4.69; N, 3.72; Found: C, 49.53; H, 4.67; N, 3.70.MS: m / z573.18.[(η 6 -bz-PA)Ru(L1)+H] + .

[0076] The Ru-PA complex was isolated as hexafluorophosphate (PF6-) salt. Its room temperature (298K) electronic absorption spectra in solvents such as water, methanol, dimethyl sulfoxide and acetonitrile are shown in Figure 2. Figure 1As shown. The significant absorption band below 300nm is attributed to the spin-allowed ligand-centered π-π* transition. The featureless band in the range of 300-360nm is caused by the π-π* ligand-centered charge transfer (LCCT) from phenyl to pyridine and the metal-to-ligand charge transfer (MLCT) transition, represented by the dπ (Ru) to π* (phenyl) transition. The bands in the visible spectrum (above 360nm) correspond to singlet and triplet MLCT transitions. The absorption spectra of Ru-PA have significant differences in solvents of different polarities. The fluorescence spectrum of Ru-PA at room temperature is shown as follows Figure 2 As shown, the results show that when excited at 405 nm, it emits fluorescence with a peak wavelength near 550 nm.

[0077] Example 2 Study on the scavenging ability of oxygen free radicals

[0078] The free radical scavenging ability of Ru-PA was determined by the ABTS method, as follows:

[0079] (1) The ABTS stock solution (5 mmol / L, dissolved in PBS) was reacted with the manganese oxide solution to form ABTS free radicals (ABTS•+).

[0080] (2) Mixing different concentrations of Ru-PA with the ABTS radical solution prepared in step (1).

[0081] (3) The absorbance at 734 nm was measured for 120 min using a cellular imaging multimode reader (Cytation 5, BioTek Instruments Inc.).

[0082] The results showed that with the increase of Ru-PA concentration and the extension of time, the absorbance of the solution gradually decreased, indicating that Ru-PA has a strong antioxidant capacity (see Figure 3 )(*** p <0.001).

[0083] Subsequently, the same method was used to conduct an in vitro free radical scavenging test of DPPH (1,1-diphenyl-2-picrylhydrazyl), and the results were the same as those of the ABTS experiment (see Figure 4 )(*** p <0.001).

[0084] To determine whether Ru-PA can scavenge ROS in cells and achieve antioxidant effects, in vitro studies were performed using the HT22 mouse hippocampal neuronal cell line. HT22 is highly sensitive to glutamate and is an effective model for in vitro oxidative stress studies. Under glutamate-induced damage, HT22 cells can produce a large amount of ROS. Therefore, HT22 cells were cultured in complete medium containing glutamate to induce damage and simulate the desired oxidative stress state. Subsequently, cells in an oxidative stress state were treated with Ru-PA. Finally, the antioxidant effect of Ru-PA in the HT22 cell line was evaluated by detecting various reactive oxygen species levels.

[0085] In order to determine the optimal working concentration of Ru-PA, the complete culture medium containing different concentrations of Ru-PA was prepared by the half-volume dilution method, and the toxicity of different concentrations of Ru-PA on HT22 cells was detected by the CCK-8 kit. According to the experimental results, the highest working concentration of Ru-PA was determined to be 62.5 μM for subsequent experiments. Next, the DCFH-DA and DHE kits were used to detect the intracellular ROS level of HT22 cells to observe the antioxidant effect of Ru-PA. The DCFH-DA kit uses the fluorescent probe DCFH-DA to detect the total ROS level. DCFH-DA enters the cell through the cell membrane and is hydrolyzed by esterase to generate DCFH. DCFH cannot penetrate the cell membrane and is therefore retained in the cell. Then, intracellular ROS converts non-fluorescent DCFH into DCF, which emits fluorescence. Therefore, the fluorescence level of intracellular DCF reflects the total intracellular ROS level. The results showed that after glutamate treatment of HT22 cells, the intracellular fluorescence intensity increased significantly, indicating that HT22 cells were in a state of strong oxidative stress. Compared with the glutamate injury group, the fluorescence intensity of cells treated with different concentrations of Ru-PA was significantly decreased (see Figure 5 ) (Ctrl (Control) is the blank control group, Inj (Injury) is the injury group, the same below; ** p <0.01,*** p <0.001), which shows that Ru-PA can reduce the level of ROS in cells and achieve antioxidant effect.

[0086] In order to improve the credibility of the experimental results, flow cytometry was also used to detect the ability of Ru-PA to reduce the level of intracellular ROS. The results were consistent with the above, that is, Ru-PA can reduce the level of intracellular ROS in HT22 cells (see Figure 6 )(** p <0.01,*** p <0.001).

[0087] Since superoxide anions are the precursors of many intracellular ROS, detecting their levels can better reflect intracellular oxidative stress. DHE is a widely used superoxide anion fluorescence detector that can be taken up by living cells and react with intracellular superoxide anions to produce products such as ethidium bromide. These products bind to RNA or DNA and produce fluorescence. The higher the level of intracellular superoxide anions, the more ethidium bromide is produced and the stronger the fluorescence. Similar to the DCFH-DA probe experiment, after treating HT22 cells in an oxidative stress state with different concentrations of Ru-PA, the intracellular fluorescence intensity was significantly lower than that of the untreated group. This shows that Ru-PA can effectively scavenge superoxide anions and reduce intracellular ROS levels (see Figure 7 ). In summary, Ru-PA can reduce the level of ROS in HT22 cells and achieve antioxidant effect.

[0088] Example 3 Study on the repair effect on neurons

[0089] The above studies show that Ru-PA has a strong antioxidant effect. Since neurons are sensitive to peroxidative environments and have low tolerance and susceptibility to oxidative stress and damage, Ru-PA has potential application prospects in the field of neuroprotection. In order to explore whether it can relieve oxidative stress by removing ROS, thereby protecting neurons and promoting the repair of neurons after injury, subsequent experiments were carried out by extracting primary neurons.

[0090] First, the toxicity of Ru-PA to neuronal cells was studied. The specific steps are as follows:

[0091] (1) The hippocampal tissue of 1-day-old Sprague-Dawley (SD) rats was minced with ophthalmic scissors and added to a 15 mL centrifuge tube (Corning). Papain (Sigma, Cat#P4762) was added and digested at 37°C for 25 min.

[0092] (2) Use bovine serum albumin to terminate the action of protease and then wash the tissue.

[0093] (3) The isolated hippocampal neurons were seeded at a concentration of 20,000 cells / mL in a 96-well plate (Corning), with 200 μL per well, and cultured in DMEM medium (with glutamine, Gibco, Carlsbad, CA, Cat#12430054) containing 10% fetal bovine serum and 10% nutrient mixture F-12 in a 37°C, 95% O2, 5% CO2 incubator for 6 h.

[0094] (4) Replace the original culture medium with Neurobasal medium containing 5% B-27 (Gibco) and culture in an incubator at 37°C, 95% O2, and 5% CO2 for 24 h.

[0095] (5) After cell adhesion, different concentrations (3.9, 7.8, 15.6, 31.3, 62.5, unit: μmol / L) of Ru-PA were added to each well and incubated for another 24 h.

[0096] (6) CCK8 kit (Beyotime, Cat#C0038) was used to assess the viability of cultured hippocampal neurons.

[0097] The results are as follows Figure 8 The results showed that at each concentration of 3.9-62.5μmol / L studied, the survival rate of hippocampal neuron cells after Ru-PA treatment was close to 100%, and there was no significant difference in survival rate compared with the blank control group ( p >0.05), Ru-PA fluorescence was absorbed by neurons and accumulated in the cytoplasm and processes of neurons, which clearly showed that it had excellent safety and had no obvious cytotoxicity to hippocampal neurons.

[0098] Subsequently, different concentrations of Ru-PA were used to treat the damaged neurons to observe its protective effect on the neurons. The specific steps are as follows:

[0099] (1) The hippocampal tissue of 1-day-old Sprague-Dawley (SD) rats was minced with ophthalmic scissors and added to a 15 mL centrifuge tube (Corning). Papain (Sigma, Cat# P4762) was added and digested at 37°C for 25 min.

[0100] (2) Use bovine serum albumin to terminate the action of protease and then wash the tissue.

[0101] (3) The isolated hippocampal neurons were seeded at a concentration of 20,000 cells / mL in a 24-well plate (Corning), with 500 μL per well, and cultured in a 37°C, 95% O2, 5% CO2 incubator for 24 h using DMEM medium (containing glutamine, Gibco, Carlsbad, CA, Cat#12430054) containing 10% fetal bovine serum and 10% nutrient mixture F-12.

[0102] (4) The original culture medium was replaced with a culture medium containing 120 μM glutamate and the cells were cultured in an incubator at 37°C, 95% O2, and 5% CO2 for 12 h to form a hippocampal neuron injury model.

[0103] (5) Different concentrations of Ru-PA (15.6, 31.3, 62.5, unit: μmol / L) were added to observe its effect on neurons. The Ctrl group served as the blank control group, in which the hippocampal neurons were not damaged.

[0104] The results are as follows Figure 9-10 As shown, the effect of Ru-PA on neurite growth was evaluated by quantifying the length and total number of branched neurites. The results showed that the length and number of neurites in glutamate-injured neurons were significantly reduced, while Ru-PA was able to promote neurite formation and neuronal neurite growth compared with glutamate-injured neurons, and this promotion was positively correlated with its concentration within a certain range. In summary, it can be clearly seen that Ru-PA treatment can significantly promote neurite formation and neuronal neurite growth, indicating that Ru-PA can repair hippocampal neuronal cells and resist damage induced by oxidative stress (** p <0.01,*** p <0.001).

[0105] Example 4 In vivo functional study

[0106] In order to explore whether Ru-PA can reduce oxidative stress and inhibit neuroinflammation in vivo, thereby protecting neurons and promoting the recovery of injured spinal cord, a mouse spinal cord injury model was established to observe the levels of oxidative stress and inflammation. The specific steps are as follows:

[0107] (1) Twenty-four 6-week-old female mice were selected and divided into four groups, with 6 mice in each group, including a blank control group (Ctrl group, 6 mice), a sham control group (Sham group, only the lamina was removed without damaging the spinal cord, 6 mice), a model group (Inj group, 6 mice), and a Ru-PA group (Inj+Ru-PA group, 6 mice) (Ru-PA 200 µL, concentration of 312.5 μM, was injected intravenously starting from the second day after spinal cord injury, once a day for 7 consecutive days). The method for constructing a mouse model of spinal cord injury is as follows:

[0108] a. Remove the hair on the back of the mouse to expose the skin on the back of the mouse;

[0109] b. Anesthesia: 1.25% tribromoethanol was injected intraperitoneally at a dose of 200 μg / 20 g. Stable breathing, significantly weakened limb muscle strength, and disappearance of pain reflex and corneal reflex indicated successful anesthesia.

[0110] c. Expose the spinal cord: wipe the skin twice with iodine cotton balls to disinfect it; determine the level of the 9th to 11th thoracic vertebrae (T9-T11), and make a 2.5 cm long longitudinal incision in the middle of the back at the T9-T11 level. Bluntly dissect the paraspinal muscles, remove the spinous processes and lamina with bone-cutting forceps, completely expose the T9-T11 segment spinal cord, use a fixator to fix the T10 plane, and remove the T10 lamina. Be careful to avoid additional tissue damage during the operation. Then use a fixator to open and fix it to fully expose the spinal cord;

[0111] d. Fix the mouse to the Louisville Injury System Apparatus (LISA), adjust the spinal cord under the impactor, and simultaneously use the monitoring laser beam to confirm the impact position, and determine the degree of spinal cord injury by the impact depth. In this embodiment, the collision tip is set to 18 psi, the impact depth is 1.0 mm, and the injury time is 0.5 s; after the collision is completed, remove the mouse from the injury device and remove it from the fixator. After sufficient hemostasis, use sutures to suture the mouse muscles and skin. Mice in the sham operation group underwent T10 laminectomy without spinal cord collision;

[0112] e. Close the incision and inject gentamicin 2000U subcutaneously once a day for 3 consecutive days. Perform artificial bladder emptying every 8 hours until spontaneous urination occurs.

[0113] (2) Small animal in vivo imaging: In vivo imaging of mice was performed on the third day after injury. First, 0.1 mL / 20 g of L-012 (chemiluminescent (CHL) probe) was intraperitoneally injected, and the concentration of L-012 was 4 mg / ml. Five minutes later, 1.25% tribromoethanol was injected intraperitoneally at a dose of 200 µg / 20 g for anesthesia. After successful anesthesia, small animal in vivo imaging was performed.

[0114] The results are as follows Fig.11 As shown. The results showed that ROS bioluminescence was rarely seen in the spinal cord of normal mice, while the bioluminescence intensity of ROS in the spinal cord of mice with spinal cord injury increased significantly and increased over time. After treatment with Ru-PA, the bioluminescence intensity of ROS decreased significantly, further confirming that Ru-PA has significant oxygen free radical scavenging and spinal cord injury repair effects in vivo (*** p <0.001).

[0115] Since Ru-PA can effectively relieve oxidative stress and inhibit neuroinflammation in mice, behavioral experiments were conducted to explore whether it can promote the recovery of lower limb motor function in mice with spinal cord injury. BMS score can be used to evaluate changes in hind limb motor function in mice with spinal cord injury, and is a reliable indicator of hind limb ankle joint activity, coordination, and claw posture. Specifically, after the SCI model was established, the lower limb movements of each group of mice were timed every three days and scored using the BMS scoring method. The results are shown in 12-13 (*** p <0.001). The results showed that the motor function of the control group and the sham operation group was not restricted, and the continuous BMS score was 9, while the BMS score of the injury group and the Ru-PA treatment group dropped to 0 after successful modeling. As time went by, the score gradually increased, and the difference between the injury group and the Ru-PA group was statistically significant. In summary, Ru-PA treatment can promote the recovery of motor function of the lower limbs of mice with spinal cord injury.

[0116] Then, a footprint test was conducted to analyze the movement of the mouse's lower limbs. Each group of mice was allowed to crawl freely on a clean paper and their footprints were recorded. The results showed that the gait of the mice in the control group and the sham operation group was normal, the mice in the injury group had a dragging phenomenon, and the gait of the mice in the Ru-PA treatment group was restored to a certain extent compared with the injury group (see Fig.14 )(*** p <0.001). Similar results were obtained in the inclined board crawling test (see Fig.15 ).

[0117] Example 5 Effect on Spinal Cord Injury

[0118] Mouse spinal cord tissue was taken for pathological study to explore the effect of Ru-PA treatment after spinal cord injury. First, the spinal cord was removed for visual inspection. The spinal cord of the injury group showed obvious cavities, while the spinal cord of the Ru-PA treatment group had fewer cavities and better integrity (see Fig.16 H&E staining showed that the continuity of the spinal cord tissue in the injury group was poor, while the Ru-PA treatment group had a certain effect on the restoration of the continuity of the spinal cord tissue (see Fig.17 ).

[0119] In order to further study the protective and repair effects of Ru-PA on spinal cord tissue, specific neural markers were used for immunohistochemical analysis. Glial fibrillary acid protein (GFAP) is mainly distributed in astrocytes in the central nervous system and is used to mark astrocytes and glial scar formation. Neurofilament protein-H (NFH) is an intermediate filament in the cytoplasm of neurons and is used to mark neurons in spinal cord tissue. The status of neurons and glial scars after spinal cord injury was observed by co-staining of GFAP and NFH. The results showed that compared with the injury group, the density of spinal cord glial scars in Ru-PA-treated mice was reduced, and the number of surviving neurons increased, suggesting that Ru-PA may inhibit the formation of glial scars and increase neuronal survival (see Fig.18 ).

[0120] After spinal cord injury, a large number of neurons with signaling functions at the site of injury are broken and die, resulting in weakened signals. Neurophysiological tests will show a decrease in the amplitude of motor evoked potentials (MEPs) and electrical conduction signals in the spinal cord. Therefore, electrophysiological tests were used to evaluate the neurological recovery of the spinal cord in mice with spinal cord injury. Specifically, electrodes were used to stimulate the cerebral cortex, receive electrical signals from the contralateral calf gastrocnemius muscle, and record motor evoked potentials. Electrodes were used to stimulate the spinal cord at the proximal end of the spinal cord injury, and electrical signals were received at the proximal end of the spinal cord injury, 2 mm distal to the injury, and 5 mm distal to the injury.

[0121] The results showed that the MEP amplitude of mice after spinal cord injury was lower than that of the control group, indicating that the corticospinal tract was significantly damaged. However, after Ru-PA treatment, the motor evoked potential was significantly restored. This indicates that Ru-PA treatment can increase the number of neurons with electrical conduction function in the anterior horn of the spinal cord (see Fig.19 ). In addition, when the spinal cord tissue proximal to the spinal cord injury site was stimulated, the amplitude of the electrical signal above the injured segment did not change significantly. The amplitude of the electrical signal received 2 mm distal to the spinal cord injury site was lower than that of the control group, indicating that neuronal damage was significant. However, after Ru-PA treatment, its amplitude increased to a certain extent, indicating that Ru-PA promoted the recovery of neurons; the amplitude of the electrical signal 5 mm distal to the spinal cord injury site also showed a similar trend (see Fig. 20 )(*** p <0.001). The above electrophysiological results show that Ru-PA treatment can promote the recovery of spinal cord signals in mice with spinal cord injury.

[0122] To further investigate whether Ru-PA is toxic to the organs of mice, sections of the organs of mice were taken on the 60th day of the experiment and observed by H&E staining. Fig.21 As shown, no pathological changes were observed in the organs, indicating that Ru-PA was biocompatible in mice, showed no obvious toxicity, and had good safety.

[0123] In summary, Ru-PA can effectively scavenge oxygen free radicals. Ru-PA treatment can promote branch formation and neurite growth, indicating that Ru-PA can repair hippocampal neuronal cells and fight against oxidative stress-induced damage. In addition, in vivo studies have shown that Ru-PA can quickly achieve functional recovery in mice with spinal cord injury, and the improvement level of BMS score is significantly improved compared with the injury group; at the same time, Ru-PA can significantly enhance the behavioral function of mice. In addition, Ru-PA can effectively reduce the bioluminescence intensity of ROS in mice with spinal cord injury, further confirming that Ru-PA has significant oxygen free radical scavenging and spinal cord injury repair effects in vivo.

[0124] The above specific implementation method part specifically introduces the analytical method involved in the present invention. It should be noted that the above introduction is only to help those skilled in the art better understand the method and ideas of the present invention, rather than limiting the relevant content. Without departing from the principle of the present invention, those skilled in the art may also make appropriate adjustments or modifications to the present invention, and the above adjustments and modifications shall also fall within the scope of protection of the present invention.

Claims

1. Use of a half-sandwich structure ruthenium complex in the preparation of a drug for preventing and / or treating diseases associated with oxidative stress, characterized in that: The structural formula of the half-sandwich structure ruthenium complex is shown below: 。 2. The use according to claim 1, characterized in that: The disease associated with oxidative stress is secondary spinal cord injury.

3. Use of a half-sandwich structure ruthenium complex in the preparation of a drug for scavenging oxygen free radicals, characterized in that: The structural formula of the half-sandwich structure ruthenium complex is shown below: 。